Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study by Yang, H., Bouma, B.J., Dimopoulos, K., Khairy, P., Ladouceur, M., Niwa, K., Greutmann, M., Schwerzmann, M., Egbe, A., Scognamiglio, G., Budts, W., Veldtman, G., Opotowsky, A.R., Broberg, C.S., Gumbiene, L., Meijboom, F.J., Rutz, T., Post, M.C., Moe, T., Lipczyńska, M., Tsai, S.F., Chakrabarti, S., Tobler, D., Davidson, W., Morissens, M., van Dijk, A., Buber, J., Bouchardy, J., Skoglund, K., Christersson, C., Kronvall, T., Konings, T.C., Alonso-Gonzalez, R., Mizuno, A., Webb, G., Laukyte, M., Sieswerda, G.T.J., Shafer, K., Aboulhosn, J., Mulder, B.J.M.

Get full text

Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease? by Yang, Hayang, Bouma, Berto J., Mulder, Barbara J. M.

Get full text